Avoidance of self-reactivity results in skewed CTL responses to rare components of synthetic immunogens

Journal of Immunology

Volumn 160, Issue 3, 1998, Pages 1085-1090

  Purcell, Anthony W ^a,e   Chen, Weisan ^a   Ede, Nicholas J ^b   Gorman, Jeffrey J ^c   Fecondo, John V ^d   Jackson, David C ^e   Zhao, Yuming ^a   McCluskey, James ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b Chiron Mimotopes Pty Ltd   (United States)

^c CSIRO   (Australia)

^d SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; N,4 TERT BUTYLASPARAGINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; ANIMALS; ASPARAGINE; AUTOANTIGENS; CHEMICAL FRACTIONATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; H-2 ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; L CELLS (CELL LINE); LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PROTEIN BINDING; RIBONUCLEOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; THYMOMA; TUMOR CELLS, CULTURED;

EID: 0031941344     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Lehner, P. J., and P. Cresswell. 1996. Processing and delivery of peptides presented by MHC class I molecules. Curr. Opin. Immunol. 8:59.
2. Madden, D. R. 1995. The three-dimensional structure of peptide-MHC complexes. Annu. Rev. Immunol. 15:587.
3. Garboczi, D. N., P. Ghosh, U. Utz, Q. R. Fan, W. E. Biddison, and D. C. Wiley. 1996. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384:134.
4. Garcia, K. C., M. Degano, R. L. Stanfield, A. Brunmark, M. R. Jackson, P. A. Peterson, L. Teyton, and I. A. Wilson. 1996. An alpha-beta T cell receptor structure at 2.5 angstrom and its orientation in the TCR-MHC complex. Science 274:209.
5. Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
6. Schild, H., M. Norda, K. Deres, K. Falk, O. Rotzschke, K. H. Wiesmuller, G. Jung, and H.-G. Rammensee. 1991. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide. J. Exp. Med. 174:1665.
7. Matsuo, H., A.-P. Batocchi, S. Hawke, M. Nicolle, L. Jacobson, A. Vincent, J. Newsom-Davis, and N. Willcox. 1995. Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor. J. Immunol. 155:3683.
8. b-binding peptides generates carbohydrate-specific, unrestricted cytotoxic T cells. Eur. J. Immunol. 26:544.
9. Deck, B., M. Elofsson, J. Kihlberg, and E. R. Unanue. 1995. Specificity of glycopeptide-specific T cell. J. Immunol. 155:1074.
10. Haurum, J. S., G. Arsequell, A. C. Lellouch, S. Y. C. Wong, R. A. Dwek, A. J. McMichael, and T. Elliot. 1994. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J. Exp. Med. 180:739.
11. Chen, W., N. J. Ede, D. C. Jackson, J. McCluskey, and A. W. Purcell. 1996. CTL recognition of an altered peptide associated with asparagine bond rearrangement: implications for immunity and vaccine design. J. Immunol. 157:1000.
12. + T cells. Immunity 3:495.
13. Tanaka, Y., C. T. Morita, Y. Tanaka, E. Nieves, M. B. Brenner, and B. R. Bloom. 1995. Natural and synthetic non-peptide antigens recognised by human γδ T cells. Nature 375:155.
14. + T cells. Nature 372:691.
15. Sieling, P. A., D. Chatterjee, S. A. Porcelli, T. I. Prigozy, R. J. Mazzaccaro, T. Soriano, B. R. Bloom, M. B. Brenner, M. Kronenberg, P. J. Brennan, and R. L. Modlin. 1995. CD1-restricted T cell recognition of microbial lipoglycan antigens. Science 269:227.
16. Meadows, L., W. Wang, J. M. M. denHaan, E. Bloklund, C. Reinhardus, J. W. Drijfhout, J. Shabanowitz, R. Pierce, A. I. Agulnik, C. E. Bishop, D. F. Hunt, E. Goulmy, and V. H. Engelhard. 1997. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 6:273.
17. Skipper, J. C. A., R. C. Hendrickson, P. H. Gulden, V. Brichard, A. Vanpel, Y. Chen, J. Shabanowitz, T. Wolfel, C. L. Slingluff, T. Boon, D. F. Hunt, and V. H. Engelhard. 1996. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183:527.
18. Schnölzer, M., P. Alewood, A. Jones, D. Alewood, and S. B. Kent. 1992. In situ neutralization in Boc-chemistry solid phase peptide synthesis: rapid, high yield assembly of difficult sequences. Int. J. Pept. Protein Res. 40:180.
19. b-restricted peptide antigen. Biomed. Pept. Proteins Nucleic Acids 1:231.
20. Chen, W., S. Khilko, J. Fecondo, D. H. Margulies, and J. McCluskey. 1994. Determinant selection of MHC class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by non-dominant anchor residues. J. Exp. Med. 180:1471.
21. + T cell fusion partner. J. Exp. Med. 170:1887.
22. Chen, W., F. R. Carbone, and J. McCluskey. 1993. Electroporation and commercial liposomes efficiently deliver soluble protein into MHC class I presentation pathway: priming in vitro and in vivo for class I-restricted recognition of soluble antigen. J. Immunol. Methods 160:49.
23. Chambers, J. C., D. Kenan, B. Martin, and J. D. Keene. 1988. Genomic structure and amino acid sequence of human La autoantigen. J. Biol. Chem. 263:18043.
24. Schnölzer, M., A. Jones, P. F. Alewood, and S. B. Kent. 1992. Ion-spray tandem mass spectrometry in peptide synthesis: structural characterisation of minor by-products in the synthesis of ACP(65-74). Anal. Biochem. 204:335.
25. Robson, V. M. J., I. D. Rae, and F. M. Ng. 1990. Identification of the aspartimide structure in a previously-reported peptide. Biol. Chem. Hoppe-Seyler 371:423.
26. Engström, U., A. Engström, A. Ernlund, B. Westermark, and C.-H. Heldin. 1992. Identification of a peptide antagonist for platelet-derived growth factor. J. Biol. Chem. 267:16581.
27. Boon, T., and P. Van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
28. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. Melief, C. Oseroff, L. Yuan, J. Ruppert, J. Sydney, M. F. Delguerao, et al. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586.